Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00231114
Registration number
NCT00231114
Ethics application status
Date submitted
30/09/2005
Date registered
4/10/2005
Date last updated
27/07/2017
Titles & IDs
Public title
Asthma Intervention Research 2 (AIR2) Trial
Query!
Scientific title
Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)
Query!
Secondary ID [1]
0
0
04-02
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Alair System
Treatment: Devices - Alair System
Experimental: Alair - Treatment of airways with the Alair System
Sham Comparator: Sham - Sham treatment of airways
Treatment: Devices: Alair System
Treatment of airways with the Alair System
Treatment: Devices: Alair System
Sham treatment of airways with the Alair System
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Integrated Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline)
Query!
Assessment method [1]
0
0
Change between Baseline and the average of 6-, 9-, and 12-month Follow-Up Visits. The AQLQ consists of 32 questions (scale from 1 to 7, where 7 reflects a higher quality of life). An increase in the AQLQ score indicates a better quality of life. The average of the 6-, 9-, and 12-month differences in the AQLQ Score are referred to as the "Integrated AQLQ Score."
Query!
Timepoint [1]
0
0
Baseline, 12 Months
Query!
Secondary outcome [1]
0
0
Percent Symptom-Free Days (Change From Baseline)
Query!
Assessment method [1]
0
0
Change between Baseline and 12-month Follow-Up Visit. Symptom-Free Days were defined as days when Subject reported no cough, wheeze, breathlessness, or sputum during the daytime, and no wheeze, cough, or awakenings due to asthma symptoms during nighttime.
Query!
Timepoint [1]
0
0
Baseline, 12 Months
Query!
Secondary outcome [2]
0
0
Total Symptom Score (Change From Baseline)
Query!
Assessment method [2]
0
0
Change from Baseline and 12-month Follow-Up Visit. Total Symptom Score comprises the sum of these six asthma symptom measurements: wheeze during the night, cough during the night, wheeze during the day, cough during the day, breathlessness during the day, and sputum production during the day. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom score represents better asthma control.
Query!
Timepoint [2]
0
0
Baseline, 12 Months
Query!
Secondary outcome [3]
0
0
Number of Puffs of Rescue Medication Used (Change From Baseline)
Query!
Assessment method [3]
0
0
Change between Baseline and 12-Month Follow-up Visit. Average number of puffs per week. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.
Query!
Timepoint [3]
0
0
Baseline, 12 Months
Query!
Secondary outcome [4]
0
0
Percent Days Rescue Medication Used (Change From Baseline)
Query!
Assessment method [4]
0
0
Change between Baseline and 12-Month Follow-up Visit. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.
Query!
Timepoint [4]
0
0
Baseline, 12 Months
Query!
Secondary outcome [5]
0
0
Asthma Control Questionnaire (ACQ) Score (Change From Baseline)
Query!
Assessment method [5]
0
0
Change between Baseline and 12-month Follow-Up Visit. The ACQ is a self-administered patient questionnaire that also includes the patient's FEV1 value (% Predicted) that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient's asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). A decrease in the ACQ score indicates better asthma control.
Query!
Timepoint [5]
0
0
Baseline, 12 Months
Query!
Secondary outcome [6]
0
0
Morning Peak Expiratory Flow (amPEF) (Change From Baseline)
Query!
Assessment method [6]
0
0
Change between Baseline and 12-month Follow-Up Visit. The peak expiratory flow rate measures the maximal rate at which a person can exhale air.
Query!
Timepoint [6]
0
0
Baseline, 12 Months
Query!
Secondary outcome [7]
0
0
Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)
Query!
Assessment method [7]
0
0
Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.
Query!
Timepoint [7]
0
0
Baseline, 12 Months
Query!
Secondary outcome [8]
0
0
Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline)
Query!
Assessment method [8]
0
0
Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.
Query!
Timepoint [8]
0
0
Baseline, 12 Months
Query!
Eligibility
Key inclusion criteria
- Subject is an adult between the ages of 18 to 65 years.
- Subject has asthma and is taking regular maintenance medication that includes Inhaled
corticosteroid (ICS) AND long acting ß2-agonist (LABA).
- Subject has a Pre-bronchodilator Forced Expiratory Volume in one second (FEV1) of
greater than or equal to 60% of predicted after medication stabilization during the
Baseline Period.
- Subject has a PC20 < 8 mg/ml per methacholine inhalation test using standardized
methods. PC20 is a provocative concentration of Provocholine® (a brand of methacholine
chloride) resulting in a drop of FEV1 of 20% or more from Baseline.
- Subject has at least two days of asthma symptoms during the 4-weeks of the Baseline
Diary Period.
- Subject is a non-smoker for 1 year or greater (if former smoker, less than 10 pack
years total smoking history).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subject has a Post-bronchodilator FEV1 of less than 65%.
- Subject has 3 or more hospitalizations for exacerbations of asthma in the previous
year; OR a history of life-threatening asthma, defined by past intubations for asthma,
or ICU admission for asthma within the prior 24 months.
- Subject has a history of recurrent lower respiratory tract infections requiring
antibiotics (more than 3 in the past 12 months).
- Subject has a history of recurrent oral steroid use for asthma (4 or more pulses of
oral steroids in the past 12 months).
- Subject has a known sensitivity to medications required to perform bronchoscopy (such
as lidocaine, atropine and benzodiazepines).
- Subject has known systemic hypersensitivity or contraindication to Methacholine
chloride or other parasympathomimetic agents.
- Subject has other medical criteria.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
297
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
John Hunter Hospital - New Lambton Heights
Query!
Recruitment hospital [2]
0
0
Sir Charles Gairdner Hospital - Perth
Query!
Recruitment hospital [3]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
2035 - New Lambton Heights
Query!
Recruitment postcode(s) [2]
0
0
6009 - Perth
Query!
Recruitment postcode(s) [3]
0
0
- Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Iowa
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Virginia
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Washington
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Wisconsin
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
RS
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Porto Alegre
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
Rio de Janeiro
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Sao Paulo
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Ontario
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Quebec
Query!
Country [27]
0
0
Denmark
Query!
State/province [27]
0
0
Odense
Query!
Country [28]
0
0
Netherlands
Query!
State/province [28]
0
0
Groningen
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Scotland
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
Birmingham
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Leicester
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
London
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boston Scientific Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objective of this randomized, double blind, sham-controlled study is to demonstrate the
safety and effectiveness of the Alair System in a population of subjects with severe asthma
who are still symptomatic despite being managed on conventional therapy of high doses of
inhaled corticosteroids and long-acting ß2-agonists.
The primary efficacy endpoint will be the difference between Study groups in the change in
Asthma Quality of Life Questionnaire (AQLQ) score from Baseline and the average score from
the 6-, 9-, and 12-month follow-up visits.
All other outcome measures assessed at 12 months post-treatment.
This will be a multicenter, randomized, double-blind, sham-controlled study comparing the
effects of treatment with the Alair System to conventional therapy of inhaled corticosteroids
(ICS) and long-acting ß2-agonists (LABA).
A Bayesian adaptive approach to sample size selection is used with a randomization scheme of
2:1 (two Alair Group Subjects for every one Control Group Subject).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00231114
Query!
Trial related presentations / publications
Pavord ID, Thomson NC, Niven RM, Corris PA, Chung KF, Cox G, Armstrong B, Shargill NS, Laviolette M; Research in Severe Asthma Trial Study Group. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol. 2013 Nov;111(5):402-7. doi: 10.1016/j.anai.2013.05.002. Epub 2013 Jun 13.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Narinder S Shargill, PhD
Query!
Address
0
0
Asthmatx, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00231114
Download to PDF